NCT07071051Recruiting
Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study
Source: ClinicalTrials.gov · Last updated 13 Feb 2026
Brief summary (registry, in English)
This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 15 (estimated)
- First submitted
- 8 Jul 2025
- Start date
- 31 Jul 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Mayo Clinic
- NCT number
- NCT07071051
What you commit to
- Study type: Observational
- Planned participants: 15
- From 31 Jul 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of systemic blood thinner within 48 hours prior to study blood draw
Other illness
- Pre-existing coagulation disorders
- Known hypersensitivity to asparaginase products
- Liver failure
- Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)
Other
- Currently pregnant
Who the study is looking for
- Age 2-21.5 years
- Confirmed diagnosis of acute lymphoblastic leukemia/lymphoma
- Planned treatment with Cal-PEG
- Informed consent obtained from parents or guardians
Age in the registry: 2 years to 22 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.